{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:12Z","timestamp":1792611672770,"version":"4.5.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Satralizumab is approved for aquaporin-4 immunoglobulin G-positive (AQP4-IgG\n                      <jats:sup>+<\/jats:sup>\n                      ) neuromyelitis optica spectrum disorder (NMOSD), but real-world data are limited. This case series aimed to describe real-world experiences with satralizumab in adults with AQP4-IgG\n                      <jats:sup>+<\/jats:sup>\n                      NMOSD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Case information for patients with AQP4-IgG\n                      <jats:sup>+<\/jats:sup>\n                      NMOSD who received satralizumab for \u22656 months was obtained from US healthcare providers over 28 months. Patient characteristics, examination findings, diagnostic tests, treatment responses, and adverse events were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 43 patients, 88% were female and 44% self-identified as Black. Median age was 54 (range, 20\u201382) years, and time since confirmed NMOSD diagnosis was 8 (1\u201318) years. Reasons for satralizumab initiation included intolerance\/safety concerns with existing therapy (30%), new diagnosis (26%), and inadequate disease control (21%). The median duration of satralizumab treatment was 31 (range, 7\u2013104) months, during which three patients (7%) had radiographically confirmed relapses and 15 (35%) experienced a related adverse event. At data cutoff, 35 patients (81%) were receiving satralizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Satralizumab was effective and well tolerated in patients with NMOSD, including those who switched from previous treatments due to inadequate disease control and\/or intolerance. These real-world outcomes align with long-term safety and efficacy findings from the Phase III SAkura trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173251386895","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:17:02Z","timestamp":1765297022000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-8254","authenticated-orcid":false,"given":"Hesham","family":"Abboud","sequence":"first","affiliation":[{"name":"Multiple Sclerosis and Neuroimmunology Program, University Hospitals Cleveland Medical Center, Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Steingo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Infinity Clinical Research, Sunrise, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Vargas","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Patel","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine"},{"name":"Emory University Hospital Midtown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-7602","authenticated-orcid":false,"given":"Mary Alissa","family":"Willis","sequence":"additional","affiliation":[{"name":"The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oklahoma Medical Research Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Khaitov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lehigh Valley Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-5359","authenticated-orcid":false,"given":"Jose","family":"Avila Ornelas","sequence":"additional","affiliation":[{"name":"Puerto Rico Multiple Sclerosis Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Subei","sequence":"additional","affiliation":[{"name":"Neurology Consultants of Dallas, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Reed","sequence":"additional","affiliation":[{"name":"Reading Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Baek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Parkside Medical Group, Upland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ochsner Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, NYU Langone Health and NYU Grossman School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-3277","authenticated-orcid":false,"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupa","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Molazadeh","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Shin","sequence":"additional","affiliation":[{"name":"University of Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Romero","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Health Science Center at San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Goulette","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Walch","sequence":"additional","affiliation":[{"name":"Memorial Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanie","family":"Cot\u00e9","sequence":"additional","affiliation":[{"name":"Memorial Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pace","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse","family":"Sengul","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Osborne","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medstar Georgetown University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Mahadeen","sequence":"additional","affiliation":[{"name":"University of Mississippi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ferayorni","sequence":"additional","affiliation":[{"name":"Genentech, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Gholizadeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Genentech, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011153"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-14"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511412995"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124"},{"key":"e_1_3_3_8_2","unstructured":"Soliris (eculizumab). Prescribing information. Alexion Pharmaceuticals. Updated June 2024 https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf (accessed 29 July 29 2024)."},{"key":"e_1_3_3_9_2","unstructured":"Ultomiris (ravulizumab-cwvz). Prescribing information. Alexion Pharmaceuticals. Updated June 2024 https:\/\/alexion.com\/Documents\/Ultomiris_USPI.pdf (accessed 29 July 29 2024)."},{"key":"e_1_3_3_10_2","unstructured":"Uplizna (inebilizumab-cdon). Prescribing information. Horizon Therapeutics. Updated July 2021 https:\/\/www.hzndocs.com\/Uplizna-Prescribing-Information.pdf (accessed 29 July 29 2024)."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02249-1"},{"key":"e_1_3_3_12_2","unstructured":"Enspryng (satralizumab-mwge). Prescribing information. Genentech Inc. Updated March 2022 https:\/\/www.gene.com\/download\/pdf\/enspryng_prescribing.pdf (accessed 29 July 29 2024)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4679"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040391"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16625-7"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.141"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1526563"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578585"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105041"},{"key":"e_1_3_3_26_2","unstructured":"Weinshenker B Yeaman M de Seze J et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): results from the phase 3 SAkuraSky and SAkuraStar studies. Poster presented at: American Academy of Neurology 2025 Annual Meeting Boston MA USA 22\u201327 April 2023 poster no. 002."},{"key":"e_1_3_3_27_2","unstructured":"Greenberg B Fujihara K Weinshenker B et al. Infection in NMOSD: an analysis of the patterns of infection in SAkuraMoon (an open-label study to evaluate the long-term safety and efficacy of satralizumab) with postmarketing data and US-based health claims data. Poster presented at: 9th Joint ECTRIMS-ACTRIMS Meeting Milan Italy 11\u201313 October 2023 poster no. P301."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","unstructured":"Palace J Traboulsee A Saiz A et al. Long-term efficacy of satralizumab in patients with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD): results from the roll-over open-label study SAkuraMoon. Poster presented at: 9th Joint ECTRIMS-ACTRIMS Meeting Milan Italy 11\u201313 October 2023 poster no. P362.","DOI":"10.1212\/WNL.0000000000202535"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75013-z"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117530"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"Traboulsee A Yeaman M Weinshenker B et al. Satralizumab in patients with neuromyelitis optica spectrum disorder and concomitant autoimmune disease. American Presented at: Academy of Neurology 2021 Annual Meeting virtual 17\u201322 April 2021 abstract no. 4118.","DOI":"10.1212\/WNL.96.15_supplement.4118"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000468"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006574"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173251386895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173251386895","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173251386895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T14:34:38Z","timestamp":1769351678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173251386895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/20552173251386895"],"URL":"https:\/\/doi.org\/10.1177\/20552173251386895","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"20552173251386895"}}